Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Sanofi's asthma drug amlitelimab shows promise, leading to further trials and exploration of related respiratory treatments.

flag Sanofi has made strides in its respiratory drug development. flag Amlitelimab, an asthma treatment, showed promising results for certain asthma patients, though primary goals were not fully met. flag The company plans to move forward with phase 3 trials for amlitelimab and is exploring other drugs, lunsekimig and itepekimab, for broader respiratory conditions including COPD and chronic rhinosinusitis, with new studies starting this year and in 2026.

3 Articles

Further Reading